---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-030154"
form_type: "8-K"
ticker: "NVNO"
cik: "0001661053"
company_name: "enVVeno Medical Corp"
filed_at: "2021-12-01T23:59:59+00:00"
generated_at: "2026-06-28T04:30:21.144048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enVVeno expects 9 SAVVE trial sites active; shareholders approve director elections, plan amendments

## Summary
- Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for terms ending at 2024 annual meeting.
- Ratified Marcum LLP as independent auditor for FY2021 with 6,085,415 for, 11,290 against, 9,074 abstain.
- Approved amendment to 2016 Omnibus Incentive Plan increasing authorized shares to 4,500,000 (2,458,617 for, 1,254,579 against).
- Approved evergreen provision requiring at least 20% fully diluted shares under plan (2,439,885 for, 1,273,777 against).
- By end of week, expects 9 sites active and enrolling in SAVVE U.S. pivotal trial for VenoValve.

## SEC filing metadata
- accession: 0001493152-21-030154
- form_type: 8-K
- ticker: NVNO
- cik: 0001661053
- company_name: enVVeno Medical Corp
- filed_at: 2021-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661053/000149315221030154/0001493152-21-030154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661053/000149315221030154/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-030154
- JSON: https://secwatch.observer/filing/0001493152-21-030154.json
- Plain text: https://secwatch.observer/filing/0001493152-21-030154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.